Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-13 |
2024-03 |
-0.38 |
-0.38 |
N/A |
N/A |
2024-03-14 |
2023-12 |
-0.47 |
-0.43 |
0.04 |
8.51% |
2024-03-14 |
2023-12 |
-0.47 |
N/A |
N/A |
N/A |
2023-11-02 |
2023-09 |
-0.53 |
-0.37 |
0.16 |
30.19% |
2023-11-02 |
2023-09 |
-0.53 |
N/A |
N/A |
N/A |
2023-08-02 |
2023-06 |
-0.59 |
-0.53 |
0.06 |
10.17% |
Date |
Firm |
Action |
From |
To |
2023-09-24 |
JP Morgan |
Upgrade |
Overweight |
Overweight |
2023-08-06 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-02 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-08-02 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-07-11 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-06-19 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-15 |
BELLDEGRUN ARIE S |
Director |
0.00 |
Stock Award(Grant) |
2024-05-15 |
CHANG DAVID D M.D., PH.D. |
Chief Executive Officer |
7.72M |
Stock Award(Grant) |
2023-08-09 |
CHEN YINLIN JACK |
Officer |
88.88K |
Stock Award(Grant) |
2024-01-24 |
DOUGLAS EARL MARTIN |
General Counsel |
477.63K |
Stock Award(Grant) |
2023-08-06 |
MAYO STEPHEN L. |
Director |
25.33K |
Sale |
2023-12-17 |
MESSEMER DEBORAH M |
Director |
62.46K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
FMR, LLC |
24.92M |
123.84M |
14.87% |
2023-06-29 |
TPG GP A, LLC |
18.72M |
93.02M |
11.17% |
2023-06-29 |
State Street Corporation |
8.48M |
42.14M |
5.06% |
2023-06-29 |
Blackrock Inc. |
8.45M |
41.98M |
5.04% |
2023-06-29 |
Vanguard Group Inc |
7.50M |
37.28M |
4.48% |
2023-06-29 |
JP Morgan Chase & Company |
6.13M |
30.49M |
3.66% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
6.43M |
25.03M |
3.84% |
2023-08-30 |
Fidelity Select Portfolios - Health Care |
4.00M |
15.56M |
2.39% |
2023-06-29 |
Vanguard Horizon Fund-Capital Opportunity Fund |
3.38M |
16.79M |
2.02% |
2023-08-30 |
Fidelity Advisor Health Care Fund |
2.88M |
11.20M |
1.72% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.35M |
11.66M |
1.40% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
2.28M |
8.86M |
1.36% |